Literature DB >> 28093446

Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival.

Natalie J Miller1, Candice D Church1, Lichun Dong2, David Crispin3, Matthew P Fitzgibbon3, Kristina Lachance1, Lichen Jing2, Michi Shinohara1, Ioannis Gavvovidis4,5, Gerald Willimsky5,6, Martin McIntosh3, Thomas Blankenstein4,5,7, David M Koelle8,9,10, Paul Nghiem11.   

Abstract

Tumor-infiltrating CD8+ T cells are associated with improved survival of patients with Merkel cell carcinoma (MCC), an aggressive skin cancer causally linked to Merkel cell polyomavirus (MCPyV). However, CD8+ T-cell infiltration is robust in only 4% to 18% of MCC tumors. We characterized the T-cell receptor (TCR) repertoire restricted to one prominent epitope of MCPyV (KLLEIAPNC, "KLL") and assessed whether TCR diversity, tumor infiltration, or T-cell avidity correlated with clinical outcome. HLA-A*02:01/KLL tetramer+ CD8+ T cells from MCC patient peripheral blood mononuclear cells (PBMC) and tumor-infiltrating lymphocytes (TIL) were isolated via flow cytometry. TCRβ (TRB) sequencing was performed on tetramer+ cells from PBMCs or TILs (n = 14) and matched tumors (n = 12). Functional avidity of T-cell clones was determined by IFNγ production. We identified KLL tetramer+ T cells in 14% of PBMC and 21% of TIL from MCC patients. TRB repertoires were strikingly diverse (397 unique TRBs were identified from 12 patients) and mostly private (only one TCRb clonotype shared between two patients). An increased fraction of KLL-specific TIL (>1.9%) was associated with significantly increased MCC-specific survival P = 0.0009). T-cell cloning from four patients identified 42 distinct KLL-specific TCRa/b pairs. T-cell clones from patients with improved MCC-specific outcomes were more avid (P < 0.05) and recognized an HLA-appropriate MCC cell line. T cells specific for a single MCPyV epitope display marked TCR diversity within and between patients. Intratumoral infiltration by MCPyV-specific T cells was associated with significantly improved MCC-specific survival, suggesting that augmenting the number or avidity of virus-specific T cells may have therapeutic benefit. Cancer Immunol Res; 5(2); 137-47. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28093446      PMCID: PMC5421625          DOI: 10.1158/2326-6066.CIR-16-0210

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  42 in total

1.  Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.

Authors:  Bianca D Lemos; Barry E Storer; Jayasri G Iyer; Jerri Linn Phillips; Christopher K Bichakjian; L Christine Fang; Timothy M Johnson; Nanette J Liegeois-Kwon; Clark C Otley; Kelly G Paulson; Merrick I Ross; Siegrid S Yu; Nathalie C Zeitouni; David R Byrd; Vernon K Sondak; Jeffrey E Gershenwald; Arthur J Sober; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2010-06-19       Impact factor: 11.527

2.  Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma.

Authors:  Natalie J Miller; Shailender Bhatia; Upendra Parvathaneni; Jayasri G Iyer; Paul Nghiem
Journal:  Curr Treat Options Oncol       Date:  2013-06

3.  MiXCR: software for comprehensive adaptive immunity profiling.

Authors:  Dmitriy A Bolotin; Stanislav Poslavsky; Igor Mitrophanov; Mikhail Shugay; Ilgar Z Mamedov; Ekaterina V Putintseva; Dmitriy M Chudakov
Journal:  Nat Methods       Date:  2015-05       Impact factor: 28.547

4.  Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens.

Authors:  Roland Houben; Masahiro Shuda; Rita Weinkam; David Schrama; Huichen Feng; Yuan Chang; Patrick S Moore; Jürgen C Becker
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

5.  Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.

Authors:  Kelly G Paulson; Jayasri G Iyer; Andrew R Tegeder; Renee Thibodeau; Janell Schelter; Shinichi Koba; David Schrama; William T Simonson; Bianca D Lemos; David R Byrd; David M Koelle; Denise A Galloway; J Helen Leonard; Margaret M Madeleine; Zsolt B Argenyi; Mary L Disis; Juergen C Becker; Michele A Cleary; Paul Nghiem
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

6.  T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors.

Authors:  Rikke Lyngaa; Natasja Wulff Pedersen; David Schrama; Charlotte Albæk Thrue; Dafina Ibrani; Ozcan Met; Per Thor Straten; Paul Nghiem; Jürgen C Becker; Sine Reker Hadrup
Journal:  Clin Cancer Res       Date:  2014-02-13       Impact factor: 12.531

7.  Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features.

Authors:  Michelle Heath; Natalia Jaimes; Bianca Lemos; Arash Mostaghimi; Linda C Wang; Pablo F Peñas; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2008-03       Impact factor: 11.527

8.  Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue.

Authors:  Andrew I Webb; Michelle A Dunstone; Weisan Chen; Marie-Isabel Aguilar; Qiyuan Chen; Heather Jackson; Linus Chang; Lars Kjer-Nielsen; Travis Beddoe; James McCluskey; Jamie Rossjohn; Anthony W Purcell
Journal:  J Biol Chem       Date:  2004-03-05       Impact factor: 5.157

9.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.

Authors:  H J Zeh; D Perry-Lalley; M E Dudley; S A Rosenberg; J C Yang
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

10.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

View more
  29 in total

Review 1.  Merkel Cell Carcinoma.

Authors:  Melissa Pulitzer
Journal:  Surg Pathol Clin       Date:  2017-03-14

Review 2.  Immunotherapy for Merkel Cell Carcinoma.

Authors:  Kotaro Nagase; Yutaka Narisawa
Journal:  Curr Treat Options Oncol       Date:  2018-09-20

3.  Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma.

Authors:  Shailender Bhatia; Natalie J Miller; Hailing Lu; Natalie V Longino; Dafina Ibrani; Michi M Shinohara; David R Byrd; Upendra Parvathaneni; Rima Kulikauskas; Jan Ter Meulen; Frank J Hsu; David M Koelle; Paul Nghiem
Journal:  Clin Cancer Res       Date:  2018-08-09       Impact factor: 12.531

4.  Impact of Tumor-Infiltrating Lymphocytes on Overall Survival in Merkel Cell Carcinoma.

Authors:  Anish A Butala; Varsha Jain; Vishruth K Reddy; Ronnie A Sebro; Yun Song; Giorgos Karakousis; Tara C Mitchell; J Nicholas Lukens; Jacob E Shabason
Journal:  Oncologist       Date:  2020-09-17

Review 5.  Innate Antiviral Immunity in the Skin.

Authors:  Chelsea Handfield; Jeffery Kwock; Amanda S MacLeod
Journal:  Trends Immunol       Date:  2018-03-08       Impact factor: 16.687

6.  Human CD4+ T Cells Specific for Merkel Cell Polyomavirus Localize to Merkel Cell Carcinomas and Target a Required Oncogenic Domain.

Authors:  Paul Nghiem; William W Kwok; David M Koelle; Natalie V Longino; Junbao Yang; Jayasri G Iyer; Dafina Ibrani; I-Ting Chow; Kerry J Laing; Victoria L Campbell; Kelly G Paulson; Rima M Kulikauskas; Candice D Church; Eddie A James
Journal:  Cancer Immunol Res       Date:  2019-08-12       Impact factor: 11.151

7.  Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients.

Authors:  C Ricci; A Righi; F Ambrosi; D Gibertoni; F Maletta; S Uccella; F Sessa; S Asioli; M Pellilli; R Maragliano; S La Rosa; M G Papotti; S Asioli
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

8.  Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus.

Authors:  Ioannis Gavvovidis; Matthias Leisegang; Gerald Willimsky; Natalie Miller; Paul Nghiem; Thomas Blankenstein
Journal:  Clin Cancer Res       Date:  2018-04-18       Impact factor: 12.531

Review 9.  Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.

Authors:  Aric Colunga; Thomas Pulliam; Paul Nghiem
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

Review 10.  Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.

Authors:  Daniela Femia; Natalie Prinzi; Andrea Anichini; Roberta Mortarini; Federico Nichetti; Francesca Corti; Martina Torchio; Giorgia Peverelli; Filippo Pagani; Andrea Maurichi; Ilaria Mattavelli; Massimo Milione; Nice Bedini; Ambra Corti; Maria Di Bartolomeo; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.